Safety Study of Bintrafusp Alfa in Combination With Other Anti-cancer Therapies in Participants With Locally Advanced or Advanced Cervical Cancer (INTR@PID 046)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bevacizumab (Primary) ; Bintrafusp alfa (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Carcinoma; Cervical cancer; Squamous cell cancer
Focus Adverse reactions
Acronyms INTR@PID 046
Sponsors EMD Serono Research & Development Institute; Merck KGaA

27 Jan 2023 Status changed from active, no longer recruiting to completed.
07 Jun 2022 Results (As of 25 Nov 2021, n=16) presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
21 May 2021 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com